EPZ5676: Potent and Selective DOT1L Inhibitor for MLL-Rearranged Leukemia

Executive Summary: EPZ5676 (SKU: A4166) is a small-molecule, SAM-competitive inhibitor of the histone methyltransferase DOT1L, showing an IC₅₀ of 0.8 nM and >37,000-fold selectivity over other methyltransferases (APExBIO product sheet). It induces cytotoxicity in acute leukemia cell lines with MLL translocations by inhibiting H3K79 methylation and downregulating MLL-fusion target genes (Ishiguro et al., 2025). In vivo, EPZ5676 causes complete tumor regression in MV4-11 xenografts without significant toxicity at 35–70 mg/kg/day intravenously for 21 days. Its mechanism extends to the modulation of innate immunity and enhancement of immunomodulatory drug efficacy in multiple myeloma. EPZ5676 is supplied by APExBIO and is validated for biochemical, cellular, and translational epigenetics research.

Biological Rationale

Histone methylation is a key epigenetic modification regulating gene expression. DOT1L (disruptor of telomeric silencing 1-like) is the sole enzyme catalyzing methylation of histone H3 at lysine 79 (H3K79), a mark associated with transcriptional activation and elongation (Ishiguro et al., 2025). Aberrant activity of DOT1L is implicated in the pathogenesis of MLL-rearranged leukemia and certain multiple myeloma subtypes. In these malignancies, DOT1L-dependent H3K79 methylation drives oncogenic gene expression programs, including IRF4-MYC signaling and the transcription of MLL-fusion target genes. Recent CRISPR screens confirm that myeloma and leukemia cells are preferentially dependent on DOT1L for survival, underscoring its value as a therapeutic target (Ishiguro et al., 2025).

Mechanism of Action of DOT1L inhibitor EPZ-5676

EPZ5676 acts as a SAM-competitive inhibitor, binding the S-adenosyl methionine site on DOT1L and inducing conformational changes that create a hydrophobic pocket inaccessible to SAM itself (APExBIO). The agent exhibits an IC₅₀ of 0.8 nM and a K_i of 80 pM for DOT1L, with >37,000-fold selectivity relative to CARM1, EHMT1/2, EZH1/2, SETD7, SMYD2/3, WHSC1/1L1, and PRMTs. In MLL-rearranged leukemia cells, EPZ5676 inhibits H3K79 methylation, leading to suppression of MLL-fusion target gene expression and pronounced cytotoxicity (IC₅₀ ~3.5 nM in MV4-11 cells after 4–7 days). In MM cells, DOT1L inhibition also activates interferon-regulated genes (IRGs), augments type I IFN responses, and downregulates IRF4 and IKZF1/3 (Ishiguro et al., 2025).

Evidence & Benchmarks

• EPZ5676 inhibits DOT1L with an in vitro IC₅₀ of 0.8 nM and K_i of 80 pM (SAM-competitive), showing >37,000-fold selectivity over related methyltransferases (APExBIO).
• In MLL-rearranged leukemia cell lines (e.g., MV4-11), EPZ5676 reduces H3K79 methylation and downregulates MLL-fusion target genes, resulting in cytotoxicity at an IC₅₀ of 3.5 nM (4–7 days exposure) (KDM2A.com).
• In vivo, intravenous administration of EPZ5676 (35–70 mg/kg/day for 21 days) in nude rat MV4-11 xenograft models led to complete tumor regression with no significant toxicity or weight loss (Ishiguro et al., 2025).
• DOT1L inhibition in multiple myeloma cells activates type I interferon responses, upregulates HLA class II genes, and enhances the efficacy of lenalidomide via IRG induction and IRF4-MYC suppression (Ishiguro et al., 2025).
• Genome-scale CRISPR knockout studies confirm DOT1L as a preferential epigenetic dependency in myeloma and MLL-leukemia cell survival (Ishiguro et al., 2025).

This dossier extends the mechanistic and translational detail provided in "DOT1L Inhibitor EPZ-5676: Decoding Mechanisms and Next-Ge..." by emphasizing new immunomodulatory findings and updated in vivo benchmarks.

For a focused comparison of workflow compatibility and specificity, see "EPZ5676: Potent and Selective DOT1L Inhibitor for MLL-Rea..."; this article clarifies translational immunology aspects not previously covered.

Applications, Limits & Misconceptions

EPZ5676 is validated for use in the following research settings:

• Biochemical enzyme inhibition assays targeting DOT1L.
• Cell-based studies of H3K79 methylation, especially in MLL-rearranged leukemia and multiple myeloma models.
• Preclinical in vivo efficacy testing in xenograft models.
• Studies of epigenetic regulation in cancer, particularly the interaction between histone methylation and immune signaling.

Common Pitfalls or Misconceptions

• EPZ5676 is not effective in cancers lacking DOT1L dependency or H3K79 methylation-driven gene expression (e.g., solid tumors without MLL rearrangements).
• It does not inhibit all histone methyltransferases; selectivity is >37,000-fold for DOT1L versus others (CARM1, EHMT1/2, etc.), so off-target effects are minimal but not zero.
• EPZ5676 is insoluble in water and must be prepared in DMSO (≥28.15 mg/mL) or ethanol (≥50.3 mg/mL with ultrasonic assistance); improper solvent use leads to precipitation or loss of activity (APExBIO).
• Cellular responses are context-dependent: non-MLL leukemia or myeloma lines may show reduced sensitivity.
• Storage of solutions above -20°C or for extended durations can cause degradation and reduced potency.

Workflow Integration & Parameters

For in vitro use, EPZ5676 is supplied as a solid (molecular weight 562.71) by APExBIO (official product page). Dissolve to ≥28.15 mg/mL in DMSO or ≥50.3 mg/mL in ethanol (with ultrasonic assistance). Stock solutions in DMSO are stable at -20°C for several months; avoid repeated freeze-thaw cycles. For cell-based assays, typical working concentrations range from 1–100 nM. For in vivo work, 35–70 mg/kg/day IV for 21 days is validated for xenograft regression. Always confirm DOT1L target dependency in the chosen cell line or model system. For detailed protocol adaptation and mechanistic insights, this article updates and extends the guidance from GTP-Binding-Protein-Fragment-G-Alpha.com by integrating new data on immunomodulatory synergy and workflow parameters.

Conclusion & Outlook

EPZ5676 (A4166) from APExBIO is a benchmark, potent, and selective DOT1L histone methyltransferase inhibitor. Its validated use in MLL-rearranged leukemia and multiple myeloma research, combined with robust biochemical, cellular, and in vivo efficacy, makes it an essential tool for epigenetics and oncology studies. Ongoing research on its immunomodulatory properties may expand its application to combination therapies and further mechanistic elucidation in immune-oncology. For ordering and technical specifications, consult the official EPZ5676 product page.